サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1696277

糖尿病デジタル治療の主要7市場（2025年～2033年）

7MM Digital Therapeutics for Diabetes Market - 2025-2033

出版日
ページ情報
英文 180 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
糖尿病デジタル治療の主要7市場（2025年～2033年）
出版日: 2025年03月25日
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

主要7市場（米国、フランス、ドイツ、イタリア、スペイン、英国、日本）の糖尿病デジタル治療の市場規模は、2024年に9億6,109万米ドルに達し、2033年までに25億7,846万米ドルに達すると予測され、予測期間の2025年～2033年にCAGRで11.7%の成長が見込まれます。

糖尿病デジタル治療とは、デジタルプラットフォームを通じて糖尿病を管理・治療するために設計された、エビデンスに基づくソフトウェア主導の介入策を指します。これらの治療は、モバイルアプリ、ウェアラブルデバイス、クラウドベースシステムなどの先進技術を使用して、個別化されたリアルタイムの治療戦略や行動介入を提供します。その目的は、データ主導の知見を活用することで、糖尿病管理を改善し、患者の転帰を向上させ、合併症を予防することです。

糖尿病デジタル治療は、ウェアラブルデバイス（持続血糖モニターなど）やユーザー入力（食事や運動など）から得られるリアルタイムのデータを利用して、個人に合わせた推奨を提供します。これにより、患者は薬物療法、食事療法、運動療法について十分な情報に基づいた決定を下し、血糖値と全体的な健康を最適化することができます。

市場力学

促進要因と抑制要因

技術的進歩が、主要7市場の糖尿病デジタル治療市場の成長を促進しています。

AI機能がデジタル治療に統合され、糖尿病や関連する慢性疾患の膨大な患者データ（グルコース値、運動、食事など）をリアルタイムで分析できるようになっています。これによって、個人の特定のニーズに適応する高度に個別化された治療計画の作成が可能になり、血糖のコントロールと長期的な健康転帰が改善されます。そのため、主な市場参入企業は、糖尿病デジタル治療の先進のAI機能に注力しています。

例えば2025年2月、在宅ケアのリーダーでありOwens & Minorファミリーの一員であるByram Healthcareは、Welldoc Appを搭載した個別化デジタルヘルスプログラムであるByramConnectを開始しました。このプログラムは、Welldoc Appの先進のAI機能を使って、1型/2型糖尿病と、高血圧、体重管理、心血管リスクなどの関連する慢性疾患を持つ人々の転帰を最適化するために、健康の6つの側面にわたって会員のデータを分析し、Byram会員に実用的な知見とレポートを提供して、医療提供者やケアチームと共有することができます。

持続血糖モニター（CGM）などのウェアラブルデバイスは、血糖値をリアルタイムで継続的に追跡します。これにより、低血糖や高血糖を防ぐためのよりよい意思決定とタイムリーな介入が可能になります。デジタル治療プラットフォームと統合されたCGMシステムは、患者と医療提供者の両方に継続的なフィードバックを提供します。この統合により、管理効率が向上し、緊急介入が減少し、患者の生活の質が向上します。小型センサーやスマートトランスミッターなどの進歩を利用したこれらの先進のCGMシステムは、市場成長の重要な動向になりつつあります。

例えば2024年10月、Ascensia Diabetes Careは、米国で糖尿病患者向けに、世界で唯一の1年CGMであるEversense 365持続血糖モニタリング（CGM）システムを発売しました。Senseonics Holdings, Inc.が開発したEversense 365は、最小限の中断で1年間の正確なモニタリングを提供する唯一のCGMであり、たった1台のCGMで自信のある意思決定、長期的な安心感、生活の質の向上を可能にします。SenseonicsのCGMシステムEversense 365には、完全に皮膚の下に挿入された小型センサーが含まれており、センサーの上に装着されたスマートトランスミッターと通信します。グルコースデータは5分ごとにユーザーのスマートフォンのモバイルアプリに自動的に送信されます。

当レポートでは、主要7市場の糖尿病デジタル治療市場について調査し、市場力学、地域とセグメントの分析、競合情勢、企業プロファイルなどを提供しています。

目次

第1章 市場のイントロダクションと範囲

第2章 エグゼクティブインサイトと重要事項

  • 市場のハイライトと戦略的ポイント
  • 主要動向と将来の予測
  • 抜粋：製品タイプ別
  • 抜粋：用途別
  • 抜粋：エンドユーザー別
  • 抜粋：国別

第3章 市場力学

  • 影響要因
    • 促進要因
      • 糖尿病の有病率の上昇
      • 技術的進歩
    • 抑制要因
      • データのプライバシーとセキュリティに関する懸念
      • 規制上の課題
    • 機会
      • 糖尿病デジタル治療におけるAI
    • 影響の分析

第4章 戦略的考察と産業の見通し

  • マーケットリーダーとパイオニア
    • 新興のパイオニアと著名企業
    • 確立されたリーダーと最大の売上を持つブランド
    • マーケットリーダーと確立された製品
  • 新興スタートアップ企業と主要イノベーター
  • CXOの視点
  • 最新の発展とブレークスルー
  • ケーススタディ/進行中の研究
  • 規制と償還の情勢
    • 米国
    • フランス
    • ドイツ
    • イタリア
    • スペイン
    • 英国
    • 日本
  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 特許分析
  • SWOT分析
  • アンメットニーズとギャップ
  • 市場参入と拡大に対し推奨される戦略
  • シナリオ分析：ベストケース、ベースケース、ワーストケースの予測
  • 価格分析と価格動向

第5章 糖尿病デジタル治療市場：製品タイプ別

  • ソフトウェアソリューション
    • モバイルアプリ
    • Webベースソリューション
  • ハードウェアソリューション
    • ウェアラブルデバイス
    • 持続血糖モニター
    • その他

第6章 糖尿病デジタル治療市場：用途別

  • 1型糖尿病
  • 2型糖尿病
  • 境界型糖尿病

第7章 糖尿病デジタル治療市場：エンドユーザー別

  • 病院
  • 専門クリニック
  • 在宅ケア環境
  • その他

第8章 糖尿病デジタル治療市場：国別

  • 米国
    • 主な国特有の力学
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • 英国
  • 日本

第9章 競合情勢と市場ポジショニング

  • 競合情勢の概要と主要市場企業
  • 市場シェア分析とポジショニングマトリクス
  • 戦略的パートナーシップ、合併・買収
  • 製品ポートフォリオとイノベーションにおける主な発展
  • 企業ベンチマーク

第10章 企業プロファイル

  • Welldoc, Inc.
  • Omada Health Inc.
  • Glooko, Inc.
  • Azumio Inc.
  • Abbott Laboratories
  • mySugr GmbH
  • Dexcom, Inc.
  • Health2Sync
  • iHealth Labs Inc.
  • Medtronic plc

第11章 前提条件と調査手法

第12章 付録

目次
Product Code: HCIT9371

The 7MM digital therapeutics for diabetes market size reached US$ 961.09 million in 2024 and is expected to reach US$ 2,578.46 million by 2033, growing at a CAGR of 11.7% during the forecast period 2025-2033.

Digital therapeutics for diabetes refer to evidence-based, software-driven interventions designed to manage and treat diabetes through digital platforms. These therapeutics use advanced technologies like mobile apps, wearable devices, and cloud-based systems to deliver personalized, real-time treatment strategies and behavioral interventions. The goal is to improve diabetes management, enhance patient outcomes, and prevent complications by leveraging data-driven insights.

Digital therapeutics for diabetes use real-time data from wearables (e.g., continuous glucose monitors) and user inputs (e.g., diet and exercise) to provide personalized recommendations. This helps patients make informed decisions about medication, diet, and physical activity, optimizing their blood glucose levels and overall health.

Market Dynamics: Drivers & Restraints

Rising technological advancements are driving the 7MM digital therapeutics for diabetes market growth

Artificial intelligence (AI) capabilities are being integrated into digital therapeutics to analyze vast amounts of patient data (e.g., glucose levels, activity, diet) in real-time for diabetes and associated chronic conditions. This enables the creation of highly personalized treatment plans that adapt to the individual's specific needs, improving glycemic control and long-term health outcomes. Thus, the key market players are focusing on the advanced artificial intelligence capabilities in their diabetes digital therapeutics.

For instance, in February 2025, Byram Healthcare, a leader in home-based care and part of the Owens & Minor family, launched ByramConnect, a personalized digital health program powered by the Welldoc App. Using the Welldoc App's advanced artificial intelligence capabilities, the program analyzes member data across six dimensions of health to help optimize outcomes for people with type 1 or type 2 diabetes and associated chronic conditions such as hypertension, weight management, and cardiovascular risk, providing Byram members with actionable insights and reports that can be shared with their providers and care teams.

Wearable devices, such as Continuous Glucose Monitors (CGMs), provide real-time, continuous tracking of glucose levels. This allows for better decision-making and timely interventions to prevent hypoglycemia or hyperglycemia. CGM systems that integrate with digital therapeutics platforms, provide continuous feedback to both patients and healthcare providers. This integration improves management efficiency, reduces emergency interventions, and enhances patient quality of life. These advanced CGM systems with advancements such as small sensors and smart transmitters becoming a key trend for market growth.

For instance, in October 2024, Ascensia Diabetes Care, launched the Eversense 365 continuous glucose monitoring (CGM) system, the world's only One-year CGM, for people with diabetes in the U.S. Developed by Senseonics Holdings, Inc., Eversense 365 is the only CGM that provides one year of accurate monitoring with minimal disruptions, enabling confident decisions, long-term peace of mind and enhanced quality of life with just one CGM. Senseonics' CGM system Eversense 365 includes a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.

Data privacy and security concerns hamper the growth of digital therapeutics for the diabetes market

Digital therapeutics platforms collect vast amounts of sensitive personal health data. Patients are often reluctant to share this data if they are unsure about how securely it is stored or who can access it. This hesitation can delay or limit the adoption of digital health solutions. Digital therapeutics platforms must comply with stringent regulations like the Health Insurance Portability and Accountability Act (HIPAA) in the U.S., the General Data Protection Regulation (GDPR) in the EU, and similar regulations in other regions. The complex compliance requirements for handling patient data can be a significant barrier to market growth, especially for smaller companies or startups.

There is a lack of universal standards for data protection and security in the digital therapeutics sector. Inconsistent practices across different companies, apps, and devices can leave vulnerabilities that may expose patient information. Cybersecurity risks are a major concern, especially as digital health platforms and wearable devices become more interconnected. Hackers targeting health data can compromise patient safety and trust in digital therapeutics.

For instance, according to the HIPAA Journal, in August 2023, 23 million breached healthcare records are reported. Over the past 12 months, an average of 9,989,003 healthcare records were breached each month. In the year to August 31, 2024, there have been 491 data breaches of 500 or more records, and at least 58,668,002 records are known to have been breached. The average breach size in 2024 is currently 119,487 records, and the median breach size is 4,109 records.

Segment Analysis

The 7MM digital therapeutics for diabetes market is segmented based on product type, application, end-user, and country.

Product Type:

The software solutions in the product type segment are expected to dominate the 7MM digital therapeutics for diabetes market with the highest market share

Software solutions are highly scalable and can be accessed by a wide range of patients, regardless of location. They can be used on mobile phones, tablets, and computers, making them accessible to a larger population, including those in remote areas. Software solutions allow for the customization of diabetes care based on real-time data, such as blood glucose levels, exercise routines, and dietary habits.

The major market players are continuously focusing on software solutions, which further accelerates the market growth. For instance, in November 2024, Medtronic received U.S. Food and Drug Administration (FDA) clearance for its new InPen smartphone app and announced the launch of its new Smart MDI system. Smart MDI was designed to provide real-time insights to users on multiple daily injection (MDI) therapy. It includes the InPen smart insulin pen, the InPen app, and Medtronic's disposable, all-in-one Simplera continuous glucose monitor (CGM), which received U.S. Food and Drug Administration approval

Software solutions enable continuous tracking of vital metrics like blood glucose levels, insulin usage and physical activity. This constant monitoring allows for immediate interventions and reduces the need for frequent in-person visits, thus enhancing patient engagement and improving long-term outcomes.

Competitive Landscape

The major players in the 7MM digital therapeutics for diabetes market include Welldoc, Inc., Omada Health Inc., Glooko, Inc., Azumio Inc., Abbott Laboratories, mySugr GmbH, Dexcom, Inc., Health2Sync, iHealth Labs Inc. and Medtronic plc and among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The 7MM digital therapeutics for diabetes market report delivers a detailed analysis with 39 key tables, more than 26 visually impactful figures and 158 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Product Type
  • 2.4. Snippet by Application
  • 2.5. Snippet by End-User
  • 2.6. Snippet by Country

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising Prevalence of Diabetes
      • 3.1.1.2. Rising Technological Advancements
    • 3.1.2. Restraints
      • 3.1.2.1. Data Privacy and Security Concerns
      • 3.1.2.2. Regulatory Challenges
    • 3.1.3. Opportunity
      • 3.1.3.1. Artificial Intelligence in Diabetes Digital Therapeutics
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with the largest selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. Emerging Startups and Key Innovators
  • 4.3. CXO Perspectives
  • 4.4. Latest Developments and Breakthroughs
  • 4.5. Case Studies/Ongoing Research
  • 4.6. Regulatory and Reimbursement Landscape
    • 4.6.1. US
    • 4.6.2. France
    • 4.6.3. Germany
    • 4.6.4. Italy
    • 4.6.5. Spain
    • 4.6.6. UK
    • 4.6.7. Japan
  • 4.7. Porter's Five Force Analysis
  • 4.8. Supply Chain Analysis
  • 4.9. Patent Analysis
  • 4.10. SWOT Analysis
  • 4.11. Unmet Needs and Gaps
  • 4.12. Recommended Strategies for Market Entry and Expansion
  • 4.13. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.14. Pricing Analysis and Price Dynamics

5. Digital Therapeutics for Diabetes Market, By Product Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 5.1.2. Market Attractiveness Index, By Product Type
  • 5.2. Software Solutions*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 5.2.3. Mobile Apps
    • 5.2.4. Web-Based Solutions
  • 5.3. Hardware Solutions
    • 5.3.1. Wearable Devices
    • 5.3.2. Continuous Glucose Monitors
    • 5.3.3. Others

6. Digital Therapeutics for Diabetes Market, By Application

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 6.1.2. Market Attractiveness Index, By Application
  • 6.2. Type-1 Diabetes*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Type-2 Diabetes
  • 6.4. Pre-Diabetes

7. Digital Therapeutics for Diabetes Market, By End-User

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 7.1.2. Market Attractiveness Index, By End-User
  • 7.2. Hospitals*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Specialty Clinics
  • 7.4. Homecare Settings
  • 7.5. Others

8. Digital Therapeutics for Diabetes Market, By Country

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.1.2. Market Attractiveness Index, By Country
  • 8.2. US*
    • 8.2.1. Introduction
    • 8.2.2. Key Country-Specific Dynamics
    • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.3. France
  • 8.4. Germany
  • 8.5. Italy
  • 8.6. Spain
  • 8.7. UK
  • 8.8. Japan

9. Competitive Landscape and Market Positioning

  • 9.1. Competitive Overview and Key Market Players
  • 9.2. Market Share Analysis and Positioning Matrix
  • 9.3. Strategic Partnerships, Mergers & Acquisitions
  • 9.4. Key Developments in Product Portfolios and Innovations
  • 9.5. Company Benchmarking

10. Company Profiles

  • 10.1. Welldoc, Inc.*
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio
      • 10.1.2.1. Product Description
      • 10.1.2.2. Product Key Performance Indicators (KPIs)
      • 10.1.2.3. Historic and Forecasted Product Sales
      • 10.1.2.4. Product Sales Volume
    • 10.1.3. Financial Overview
      • 10.1.3.1. Company Revenue
      • 10.1.3.2. Geographical Revenue Shares
      • 10.1.3.3. Revenue Forecasts
    • 10.1.4. Key Developments
      • 10.1.4.1. Mergers & Acquisitions
      • 10.1.4.2. Key Product Development Activities
      • 10.1.4.3. Regulatory Approvals, etc.
    • 10.1.5. SWOT Analysis
  • 10.2. Omada Health Inc.
  • 10.3. Glooko, Inc.
  • 10.4. Azumio Inc.
  • 10.5. Abbott Laboratories
  • 10.6. mySugr GmbH
  • 10.7. Dexcom, Inc.
  • 10.8. Health2Sync
  • 10.9. iHealth Labs Inc.
  • 10.10. Medtronic plc

LIST NOT EXHAUSTIVE

11. Assumption and Research Methodology

  • 11.1. Data Collection Methods
  • 11.2. Data Triangulation
  • 11.3. Forecasting Techniques
  • 11.4. Data Verification and Validation

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us